Table 2.
Common Adverse Events and Those Resulting in Treatment Discontinuation in a Study Comparing Atazanavir Boosted by Cobicistat with Atazanavir Boosted by Ritonavir
| Cobicistat-Boosted (n = 344) | Ritonavir-Boosted (n = 348) | |
|---|---|---|
| Adverse Events Affecting ≥ 10% of Subjects | ||
| Bilirubin-relateda | 41% | 36% |
| Nausea | 18% | 16% |
| Diarrhea | 15% | 20% |
| Headache | 11% | 16% |
| Nasopharyngitis | 11% | 15% |
| Upper respiratory infection | 10% | 8% |
| Adverse Events Leading to Treatment Discontinuation (n) | ||
| Study drug discontinuation due to any adverse event | 7.3% (25) | 7.2% (25) |
| Bilirubin-relateda | 3.5% (12) | 3.2% (11) |
| Renal abnormalities | 1.7% (6) | 1.4% (5) |
| Rash | 0.3% (1) | 0.6% (2) |
| Dermatitis allergic | 0.6% (2) | 0 |
a
Bilirubin-related adverse events include jaundice, ocular icterus, hyperbilirubinemia, and increased blood bilirubin level. Adapted with permission from Gallant et al.4